Inspyr Therapeutics, Inc. (NSPX) financial statements (2021 and earlier)

Company profile

Business Address 2629 TOWNSGATE RD, SUITE 215
WESTLAKE VILLAGE, CA 91361
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments0000000
Cash and cash equivalents0000000
Restricted cash and investments 000000
Total current assets:0000000
Noncurrent Assets
Property, plant and equipment    (0)(0)0
Intangible assets, net (including goodwill)    (0)00
Intangible assets, net (excluding goodwill)    (0)00
Other undisclosed noncurrent assets    00 
Total noncurrent assets:     00
TOTAL ASSETS:0000000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4444444
Accounts payable2222222
Accrued liabilities2222222
Debt2232333
Derivative instruments and hedges, liabilities7132212
Total current liabilities:137109999
Noncurrent Liabilities
Total liabilities:137109999
Stockholders' equity
Stockholders' equity attributable to parent(13)(7)(10)(9)(9)(8)(9)
Common stock0000000
Additional paid in capital54535353525252
Accumulated deficit(67)(60)(63)(61)(61)(60)(61)
Total stockholders' equity:(13)(7)(10)(9)(9)(8)(9)
TOTAL LIABILITIES AND EQUITY:0000000

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Operating expenses(2)(0)(0)(0)(0)(0)(0)
Operating loss:(2)(0)(0)(0)(0)(0)(0)
Interest and debt expense(0)0 00  
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes(4)2(1)(1)(0)1(1)
Net income (loss) attributable to parent:(7)2(1)(1)(0)0(1)
Other undisclosed net loss available to common stockholders, basic(0)   (0)  
Net income (loss) available to common stockholders, basic:(7)2(1)(1)(0)0(1)
Interest on convertible debt 2     
Other undisclosed net income (loss) available to common stockholders, diluted1(5)     
Net income (loss) available to common stockholders, diluted:(6)(0)(1)(1)(0)0(1)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net income (loss):(7)2(1)(1)(0)0(1)
Comprehensive income (loss), net of tax, attributable to parent:(7)2(1)(1)(0)0(1)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: